<DOC>
	<DOCNO>NCT02466997</DOCNO>
	<brief_summary>Multicentric French parallel double-blind randomized versus placebo study</brief_summary>
	<brief_title>Efficacy Tacrolimus Adults With Facial Non-segmental Vitiligo - VITAC</brief_title>
	<detailed_description>Multicentric French parallel double-blind randomized versus placebo study , duration treatment 6 month , post-treatment follow-up period 6 month</detailed_description>
	<mesh_term>Vitiligo</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>1 . Subject male female age 18 year old 2 . Diagnosis nonsegmental ( symmetrical ) vitiligo 3 . Presence least one vitiligo targetplaque face , : Area great 3cm² Local Vitiligo Area Severity Index ( VASI ) score ≥ 50 % Stable ( change pigmentation size last 3 month ) Recent onset ( less 2 year duration ) 4 . Subject affiliated French social security system 1 . Progressive vitiligo last 3 month 2 . Spontaneous ongoing repigmentation ( document last 3 month ) 3 . Previous topical Tacrolimus treatment last 3 month 4 . Previous topical systemic treatment last month : Topical oral corticosteroid Topical vitamin D Phototherapy laser Other topical treatment specific vitiligo Other immunosuppressant immunomodulator 5 . Underlying dermatological disease ( i.e . : history atopic dermatitis , eczema , psoriasis ) , , accord investigator , could interfere study assessment 6 . Known sensitivity study drug macrolides 7 . Past history skin cancer lymphoma 8 . Congenital acquire immunodeficiency 9 . Pregnant breastfeed woman 10 . Women without contraception 11 . Absence sign informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Vitiligo</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Face</keyword>
</DOC>